BR112022010798A2 - Derivado de metileno-naftaleno-éter de fenilisoxazolila, seu uso e composição farmacêutica compreendendo o mesmo - Google Patents
Derivado de metileno-naftaleno-éter de fenilisoxazolila, seu uso e composição farmacêutica compreendendo o mesmoInfo
- Publication number
- BR112022010798A2 BR112022010798A2 BR112022010798A BR112022010798A BR112022010798A2 BR 112022010798 A2 BR112022010798 A2 BR 112022010798A2 BR 112022010798 A BR112022010798 A BR 112022010798A BR 112022010798 A BR112022010798 A BR 112022010798A BR 112022010798 A2 BR112022010798 A2 BR 112022010798A2
- Authority
- BR
- Brazil
- Prior art keywords
- phenylisoxazolyl
- naphthalene
- methylene
- pharmaceutical composition
- ether derivative
- Prior art date
Links
- -1 PHENYLISOXAZOLYL Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 208000002672 hepatitis B Diseases 0.000 abstract 3
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Control Of El Displays (AREA)
- Control Of Indicators Other Than Cathode Ray Tubes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
DERIVADO DE METILENO-NAFTALENO-ÉTER DE FENILISOXAZOLILA, SEU USO E COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO O MESMO. A presente invenção fornece um método para tratar ou prevenir infecção pelo vírus da hepatite B em um humano ou animal, compreendendo administrar ao humano ou animal em necessidade do mesmo uma quantidade terapeuticamente eficaz de um derivado de fenilisoxazolil metileno-naftaleno-éter tendo uma estrutura de fórmula (I); uso de um derivado de fenilisoxazolil metileno-naftaleno-éter tendo uma estrutura de fórmula (I) na preparação de uma composição farmacêutica para o vírus anti-hepatite B e uma composição farmacêutica para o vírus anti-hepatite B.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2019/122595 WO2021108974A1 (en) | 2019-12-03 | 2019-12-03 | Compounds for modulating activity of fxr and uses thereof |
| PCT/CN2020/120370 WO2021109713A1 (en) | 2019-12-03 | 2020-10-12 | Use and pharmaceutical composition of phenylisoxazolyl methylene-naphthalene-ether derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022010798A2 true BR112022010798A2 (pt) | 2022-08-23 |
Family
ID=76111005
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022010798A BR112022010798A2 (pt) | 2019-12-03 | 2020-10-12 | Derivado de metileno-naftaleno-éter de fenilisoxazolila, seu uso e composição farmacêutica compreendendo o mesmo |
| BR112022010638A BR112022010638A2 (pt) | 2019-12-03 | 2020-10-12 | Compostos para modular a atividade de fxr e usos dos mesmos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022010638A BR112022010638A2 (pt) | 2019-12-03 | 2020-10-12 | Compostos para modular a atividade de fxr e usos dos mesmos |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20230165843A1 (pt) |
| EP (2) | EP4073070A4 (pt) |
| JP (2) | JP2023505205A (pt) |
| KR (2) | KR20220112278A (pt) |
| CN (2) | CN112891348B (pt) |
| AU (2) | AU2020395393B2 (pt) |
| BR (2) | BR112022010798A2 (pt) |
| CA (2) | CA3159899A1 (pt) |
| CO (2) | CO2022008701A2 (pt) |
| IL (2) | IL293507A (pt) |
| MX (2) | MX2022006653A (pt) |
| PE (2) | PE20230182A1 (pt) |
| WO (3) | WO2021108974A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021108974A1 (en) * | 2019-12-03 | 2021-06-10 | Gannex Pharma Co., Ltd | Compounds for modulating activity of fxr and uses thereof |
| TWI845975B (zh) * | 2021-07-06 | 2024-06-21 | 中國大陸商甘萊製藥有限公司 | 用於治療肝臟疾病的聯合治療 |
| TW202315608A (zh) * | 2021-07-06 | 2023-04-16 | 中國大陸商甘萊製藥有限公司 | 用於治療肝臟疾病的聯合治療 |
| MX2024002982A (es) * | 2021-09-09 | 2024-04-30 | Gannex Pharma Co Ltd | Una composición farmacéutica del agonista fxr y su método de preparación. |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110034507A1 (en) * | 2007-07-02 | 2011-02-10 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
| BR112016005507B1 (pt) * | 2013-09-11 | 2023-02-07 | Centre National De La Recherche Scientifique (Cnrs) | Uso de um agonista do receptor farnesoide x (fxr) |
| WO2016024010A1 (en) * | 2014-08-14 | 2016-02-18 | Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) | Perk activator for the treatment of neurodegenerative diseases |
| WO2017189652A1 (en) * | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| US10080743B2 (en) * | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| WO2018190643A1 (en) * | 2017-04-12 | 2018-10-18 | Il Dong Pharmaceutical Co., Ltd. | An isoxazole derivatives as nuclear receptor agonists and used thereof |
| WO2019160813A1 (en) * | 2018-02-14 | 2019-08-22 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2021108974A1 (en) * | 2019-12-03 | 2021-06-10 | Gannex Pharma Co., Ltd | Compounds for modulating activity of fxr and uses thereof |
-
2019
- 2019-12-03 WO PCT/CN2019/122595 patent/WO2021108974A1/en active Application Filing
-
2020
- 2020-10-12 KR KR1020227022709A patent/KR20220112278A/ko not_active Application Discontinuation
- 2020-10-12 US US17/781,730 patent/US20230165843A1/en active Pending
- 2020-10-12 EP EP20895007.1A patent/EP4073070A4/en active Pending
- 2020-10-12 CA CA3159899A patent/CA3159899A1/en active Pending
- 2020-10-12 MX MX2022006653A patent/MX2022006653A/es unknown
- 2020-10-12 CN CN202011083652.8A patent/CN112891348B/zh active Active
- 2020-10-12 WO PCT/CN2020/120369 patent/WO2021109712A1/en active Application Filing
- 2020-10-12 IL IL293507A patent/IL293507A/en unknown
- 2020-10-12 AU AU2020395393A patent/AU2020395393B2/en active Active
- 2020-10-12 CN CN202011084166.8A patent/CN112898289B/zh active Active
- 2020-10-12 EP EP20896203.5A patent/EP4073071A4/en active Pending
- 2020-10-12 IL IL293497A patent/IL293497A/en unknown
- 2020-10-12 WO PCT/CN2020/120370 patent/WO2021109713A1/en active Application Filing
- 2020-10-12 JP JP2022533371A patent/JP2023505205A/ja active Pending
- 2020-10-12 PE PE2022001013A patent/PE20230182A1/es unknown
- 2020-10-12 US US17/756,789 patent/US20220388997A1/en active Pending
- 2020-10-12 KR KR1020227020581A patent/KR20220101697A/ko active Search and Examination
- 2020-10-12 CA CA3163779A patent/CA3163779A1/en active Pending
- 2020-10-12 BR BR112022010798A patent/BR112022010798A2/pt unknown
- 2020-10-12 AU AU2020397245A patent/AU2020397245B2/en active Active
- 2020-10-12 JP JP2022533383A patent/JP7430263B2/ja active Active
- 2020-10-12 BR BR112022010638A patent/BR112022010638A2/pt unknown
- 2020-10-12 PE PE2022001004A patent/PE20230235A1/es unknown
- 2020-10-12 MX MX2022006742A patent/MX2022006742A/es unknown
-
2022
- 2022-06-22 CO CONC2022/0008701A patent/CO2022008701A2/es unknown
- 2022-06-22 CO CONC2022/0008719A patent/CO2022008719A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022010798A2 (pt) | Derivado de metileno-naftaleno-éter de fenilisoxazolila, seu uso e composição farmacêutica compreendendo o mesmo | |
| BR112018075682A2 (pt) | inibidores de papd5 e papd7 para tratamento de infecção pela hepatite b | |
| CY1118059T1 (el) | Συνθεσεις αντιλοιμωδων βασει λιπιδιων για αγωγη πνευμονικων λοιμωξεων | |
| BR112022026321A2 (pt) | Análogos de 1'-ciano nucleosídeo e usos dos mesmos | |
| BR0315937A (pt) | Composto, composição para a profilaxia ou tratamento de infecções virais, e, método para a profilaxia ou tratamento de infecções da hepatite c e doenças associadas com tais infecções em um hospedeiro vivo | |
| BR112021022624A2 (pt) | Compostos para o tratamento da doença de huntington | |
| BR9913157A (pt) | Processos para tratar ou previnir infecção causada por pelo menos um vìrus das flaviviridae e doenças associadas com a referida infecção e infecção causada por pelo menos um vìrus do gênero hepacivìrus da flaviviridade e doenças associadas com a referida infecção, composição farmacêutica para tratar ou previnir infecções virais, e, composto | |
| BRPI0509467A (pt) | compostos macrocìclicos como inibidores de replicação viral | |
| MX2022011111A (es) | Métodos para tratar infección de coronavirus y lesión pulmonar inducida por inflamación resultante. | |
| WO2005020884A3 (en) | Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses | |
| BR112015026006A8 (pt) | composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit | |
| BR112012022311A2 (pt) | agentes farmacêuticos de combinação como inibidores da replicação de hcv. | |
| BR112021017415A2 (pt) | Derivados de pirimidona de anel fundido para uso no tratamento de infecção por vhb ou de doenças induzidas por vhb | |
| BR112023002951A2 (pt) | Compostos de fosfolipídio e usos destes | |
| BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
| BR112021022889A8 (pt) | Derivados heterocíclicos fundidos, seus usos, composição farmacêutica e produto compreendendo os mesmos e método para a preparação dos mesmos | |
| BR112022001567A2 (pt) | Derivados de isoquinolina e seu uso para o tratamento de infecções parasitárias. | |
| BR112019018615A2 (pt) | compostos antimicrobianos, composições e usos dos mesmos | |
| BR112022017923A2 (pt) | Tratamento de infecção por coronavírus | |
| BR112022015771A2 (pt) | Compostos tetracíclicos para tratar a infecção por hiv | |
| BR112022016131A2 (pt) | Compostos para tratamento de infecção por coronavírus | |
| BR112015023806A2 (pt) | Novos regimes de dosagem de celgosivir para o tratamento de dengue | |
| BR112022005941A2 (pt) | Compostos do conjugado para prevenir e/ou tratar infecções por hbv e/ou hdv, doenças hepáticas e para direcionar ntcp | |
| BRPI0508079A (pt) | composto ou uma forma cristalina ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos de tratar ou prevenir uma infecção viral com hepatite c em um mamìfero e de inibir replicação de um vìrus da hepatite c | |
| BR112022019357A2 (pt) | Medicamento/agente para o tratamento de coronavírus, infecções retrovirais e hepatite c |